Companies › IDP Discovery Pharma
1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jul 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| IDP-121 cMyc protein antagonist | MYC | Phase 1 | Multiple Myeloma (MM); Small Cell Lung Cancer ( SCLC ) | Jul 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05908409 | IDP-121 | Phase 1 | Multiple Myeloma (MM) | Oncology | Dec 2025 |
| NCT07864207 | IDP-121 | Phase 1 | Small Cell Lung Cancer ( SCLC ) | Oncology | Jul 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.